Understand the source comparison
ARA-290 for Inflammation Protocol: Peptide vs Traditional Anti-Inflammatory Comparison
Primary Target Innate repair receptor (CD131/βc heterodimer) Glucocorticoid receptor (broad transcriptional suppression) COX-1/COX-2 enzymes (prostaglandin synthesis) ARA-290 modulates repair signaling without suppressing immune function. Mechanistically disti
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Primary Target
- Innate repair receptor (CD131/βc heterodimer)
- Glucocorticoid receptor (broad transcriptional suppression)
- COX-1/COX-2 enzymes (prostaglandin synthesis)
- ARA-290 modulates repair signaling without suppressing immune function. Mechanistically distinct from both corticosteroids and NSAIDs
- Effect on Cytokines
- Reduces IL-6, TNF-α by 40–60% via macrophage polarisation shift (M1→M2)
- Broad suppression of pro-inflammatory cytokines (60–80% reduction)
- Minimal direct cytokine effect. Reduces downstream prostaglandin-mediated inflammation
- Corticosteroids produce stronger cytokine suppression but at the cost of immune compromise; ARA-290 effect is more selective
- Immune System Impact
- Preserves immune function. No T-cell suppression or infection risk elevation
- Dose-dependent immunosuppression. Increases infection risk, delays wound healing
- No systemic immunosuppression
- ARA-290's tissue-protective mechanism doesn't impair pathogen response. A critical distinction in contexts where immune competence must be maintained
- Application Timing
- Most effective within 24–48 hours of inflammatory insult (acute phase)
- Effective at any inflammatory stage but chronic use causes adverse effects
- Effective for symptom management but doesn't alter inflammatory resolution timeline
- ARA-290's timing dependency makes it ideal for acute injury models; less suited for chronic inflammatory conditions already in steady state
- Dosing Frequency
- Daily or every 48 hours for 5–14 days
- Daily to multiple times daily (dose-dependent)
- Multiple times daily (short half-life)
- ARA-290's extended signaling window (24–48 hours post-dose) allows less frequent administration than NSAIDs